科前生物
(688526)
| 流通市值：74.86亿 | | | 总市值：74.86亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 737,863,251.81 | 487,290,650.57 | 245,188,828.52 | 941,923,862.86 |
| 营业收入 | 737,863,251.81 | 487,290,650.57 | 245,188,828.52 | 941,923,862.86 |
| 二、营业总成本 | 401,181,258.98 | 257,541,676.39 | 133,324,710.25 | 547,793,468.42 |
| 营业成本 | 243,795,691.84 | 159,428,789.3 | 83,667,726.68 | 341,394,102.64 |
| 税金及附加 | 4,947,850.1 | 3,226,287.12 | 1,624,952.64 | 6,175,244.01 |
| 销售费用 | 81,234,910.86 | 51,325,590.19 | 27,319,280.7 | 114,045,783.13 |
| 管理费用 | 43,466,248.18 | 29,219,952.79 | 14,372,200.88 | 61,639,233.33 |
| 研发费用 | 71,872,613.35 | 45,497,479.23 | 21,330,798.19 | 86,121,440.39 |
| 财务费用 | -44,136,055.35 | -31,156,422.24 | -14,990,248.84 | -61,582,335.08 |
| 其中:利息费用 | 269,451.82 | 147,328.99 | 75,256.86 | 4,769,834.14 |
| 其中:利息收入 | 45,438,279.37 | 31,413,860.49 | 15,099,461.19 | 66,557,040.92 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 27,620,436.69 | 13,267,119.68 | 4,637,893.94 | 30,986,081.97 |
| 加:投资收益 | -9,564,186.97 | 3,572,559.49 | 1,485,275.25 | 6,616,220.42 |
| 资产处置收益 | - | 0 | - | 926,906.06 |
| 资产减值损失(新) | -7,925,846.66 | -671,363.37 | -4,320,266.79 | -16,080,317.97 |
| 信用减值损失(新) | 28,550,162.64 | 885,962.71 | 9,056,930.53 | -12,387,446.79 |
| 其他收益 | 14,949,832.51 | 6,939,358.55 | 2,949,688.73 | 34,655,817.28 |
| 四、营业利润 | 390,312,391.04 | 253,742,611.24 | 125,673,639.93 | 438,847,655.41 |
| 加:营业外收入 | 136,511.44 | 97,257.97 | 47,370.4 | 167,637.96 |
| 减:营业外支出 | 1,477,570.85 | 264,961.24 | 225,959.33 | 882,440.48 |
| 五、利润总额 | 388,971,331.63 | 253,574,907.97 | 125,495,051 | 438,132,852.89 |
| 减:所得税费用 | 52,366,559.79 | 34,297,146.77 | 17,708,778.25 | 56,643,206.58 |
| 六、净利润 | 336,604,771.84 | 219,277,761.2 | 107,786,272.75 | 381,489,646.31 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 336,604,771.84 | 219,277,761.2 | 107,786,272.75 | 381,489,646.31 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 337,791,776.24 | 219,896,297.5 | 108,236,874.48 | 382,350,180.06 |
| 少数股东损益 | -1,187,004.4 | -618,536.3 | -450,601.73 | -860,533.75 |
| 扣除非经常损益后的净利润 | 274,582,316.3 | 189,959,243.54 | 91,609,574.49 | 311,886,194.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.72 | 0.47 | 0.23 | 0.82 |
| (二)稀释每股收益 | 0.72 | 0.47 | 0.23 | 0.82 |
| 八、其他综合收益 | 47,672,522.15 | 50,736,402.83 | 15,356,455.6 | -42,473,821.86 |
| 归属于母公司股东的其他综合收益 | 47,672,522.15 | 50,736,402.83 | 15,356,455.6 | -42,473,821.86 |
| 九、综合收益总额 | 384,277,293.99 | 270,014,164.03 | 123,142,728.35 | 339,015,824.45 |
| 归属于母公司股东的综合收益总额 | 385,464,298.39 | 270,632,700.33 | 123,593,330.08 | 339,876,358.2 |
| 归属于少数股东的综合收益总额 | -1,187,004.4 | -618,536.3 | -450,601.73 | -860,533.75 |
| 公告日期 | 2025-10-30 | 2025-08-26 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |